APIE-logo.png
APIE Therapeutics Appoints Ashwin Datt Chief Executive Officer
July 11, 2023 08:00 ET | APIE Therapeutics
Research Triangle Park, NC, July 11, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical regenerative medicines company, today announced the appointment of industry veteran, Ashwin...
APIE-logo.png
APIE Therapeutics Welcomes Jim Greenwood to its Board of Directors
March 21, 2023 08:00 ET | APIE Therapeutics
Cary, NC, March 21, 2023 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), announced...
APIE-logo.png
APIE Therapeutics Provides Evidence that Activating the Apelinergic System can Repair and Regenerate Lung Tissue Damaged by Pulmonary Fibrosis
August 30, 2022 08:00 ET | APIE Therapeutics
CARY, NC , Aug. 30, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics (APIE Tx), a preclinical pharmaceutical company pioneering novel and proprietary drugs to activate the apelin receptor (APJ), presented...
APIE-logo.png
APIE Therapeutics Presented Preclinical Findings Supporting Activation of the Apelin Receptor as a Therapeutic Approach for Systemic Sclerosis
August 02, 2022 10:15 ET | APIE Therapeutics
Cary, NC, Aug. 02, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical pharmaceutical company pioneering novel and proprietary anti-fibrotic drugs that target the apelin receptor (APJ),...
APIE-logo.png
APIE Therapeutics Augments Leadership Team with Addition of Chief Business Officer and Chief Medical Officer
January 12, 2022 07:30 ET | APIE Therapeutics
Cary, NC, Jan. 12, 2022 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...
APIE-logo.png
APIE Therapeutics Prepares to Advance Pipeline Programs with Appointment of Robert Willette, Ph.D. as Chief Scientific Officer
March 18, 2021 08:11 ET | APIE Therapeutics
Cary, NC, March 18, 2021 (GLOBE NEWSWIRE) -- APIE Therapeutics, a preclinical biopharma company pioneering microvasculature endothelium drug development by targeting the apelin receptor (APJ),...